GlassScriptPhysician profile
Deepak S Patel
NPI 1457346074
$10,435.13
in general payments reported to CMS, 2019-2025
46 companies · $1,475 in 2025
The $1,475 reported for 2025 was more than what 93% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,366 · 2020: $1,129 · 2021: $1,415 · 2022: $1,495 · 2023: $1,841 · 2024: $1,714 · 2025: $1,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,030.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,030.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,485.74 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $1,310.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,107.45 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $941.29 | 2021-2025 | |
| Lilly USA, LLC | $904.39 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $806.04 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $601.50 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $459.60 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Astrazeneca Pharmaceuticals LP | $452.90 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Gilead Sciences, INC. | $322.40 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $253.26 | 2019-2022 | |
| Exact Sciences Corporation | $185.51 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Cranial Technologies, INC | $166.34 | 2019-2025 | Doc Band |
| Astellas Pharma US INC | $128.23 | 2019-2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $116.94 | 2021-2025 | Eliquis, Camzyos |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.